Patents Assigned to Ablynx N.V.
  • Biological materials related to c-Met
    Patent number: 9346884
    Abstract: The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: May 24, 2016
    Assignee: Ablynx N.V.
    Inventors: Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Cedric Jozef Neotere Ververken, Tinneke Denayer
  • Pulmonary administration of immunoglobulin single variable domains and constructs thereof
    Patent number: 9320792
    Abstract: In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: April 26, 2016
    Assignee: Ablynx N.V.
    Inventors: Marie-Paule Lucienne Armanda Bouche, Peter Vanlandschoot, Erwin Sablon, Erik Depla, Stefan De Buck, Xavier Saelens, Bert Schepens, Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen, Hans De Haard
  • STABLE FORMULATIONS OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND USES THEREOF
    Publication number: 20160090424
    Abstract: The present invention relates to stable formulations of polypeptides, e.g. immunoglobulin single variable domains, in particular immunoglobulin single variable domains directed against von Willebrand Factor (vWF). The invention provides formulations which are stable upon storage for prolonged periods of time and over a broad range of temperatures. The formulations of the invention ensure a high stability of the polypeptide, allowing multiple freeze-thaw cycles without chemical or physical deterioration, and provide stability in relation to mechanical stress, such as shake, shear or stir stress. They are suitable for pharmaceutical and diagnostic preparations and compatible with pharmaceutically acceptable diluents.
    Type: Application
    Filed: May 16, 2014
    Publication date: March 31, 2016
    Applicant: Ablynx N.V.
    Inventors: Yves Meyvis, Veronique De Brabandere, Hans Ulrichts, Ann Brige, Filip Callewaert
  • Methods of using IL-6R antibodies to block or reduce binding of IL-6 to IL-6R
    Patent number: 9273150
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: March 1, 2016
    Assignee: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
  • Stable formulations of polypeptides and uses thereof
    Patent number: 9265834
    Abstract: Formulations are provided that contain single variable domains with a good solubility and good stability under different storage, transportation and stress conditions. The formulations are useful as pharmaceutical formulation. The formulation comprises an aqueous carrier with a pH of 5.5 to 8.0, a buffer selected from the group consisting of histidine pH 6.0-6.5, hepes pH 7.0-8.0, MES pH 6.0, succinate pH 6.0-6.5 and acetate pH 5.5-6.0; an excipient; and/or a surfactant selected from polysorbate 80, polysorbate 20 and poloxamers. The formulation is further characterized that it has an inorganic salt concentration of 150 mM or lower.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: February 23, 2016
    Assignee: Ablynx N.V.
    Inventors: Ann Brige, Christine Labeur, Veronique De Brabandere, Marc Lauwereys
  • Method for generation of immunoglobulin sequences
    Patent number: 9260508
    Abstract: The present invention relates to a method for generating immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored. The invention also provides immunoglobulin sequences obtainable by the method of the invention. Specifically, the present invention relates to the generation of immunoglobulin sequences by use of DNA vaccination. More specifically, the present invention relates to generation of immunoglobulin sequences in camelids, preferably directed against cell-associated antigens, in particular antigens with multiple transmembrane spanning domains, including GPCRs and ion channels, by DNA vaccination. Furthermore, the present invention relates to said immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored, such as e.g. GPCRs and ion channels, more preferably ion channels.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: February 16, 2016
    Assignee: Ablynx N.V.
    Inventors: Toon Laeremans, Catelijne Stortelers, Friedrich Nolte, Maria Gonzalez Pajuelo, Joana Assunção, Philippe Van Rompaey
  • Polypeptide constructs including VHH directed against EGFR for intracellular delivery
    Patent number: 9243065
    Abstract: The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further relates to a method for delivering therapeutic molecules to the interior of cells. The invention further relates to polypeptide constructs including VHH directed against EGFR.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: January 26, 2016
    Assignee: Ablynx N.V.
    Inventors: Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen
  • A-beta binding polypeptides
    Patent number: 9211330
    Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: December 15, 2015
    Assignee: Ablynx N.V.
    Inventors: John E. Park, Cornelia Dorner-Ciossek, Stefan Hoerer, Lothar Kussmaul, Martin Lenter, Katharina Zimmerman, Gerald Beste, Toon Laeremans, Pascal Gerard Merchiers, Jo Vercammen
  • Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
    Patent number: 9212226
    Abstract: The present invention relates to amino acid sequences that are directed against (as defined herein) G-protein coupled receptors (GPCRs) and in particular to CXCR4 and CXCR7, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively). Furthermore, the invention provides a new method of making amino acid sequences that are directed against transmembrane protein, and in particular for multiple spanning transmembrane proteins for which the native conformation cannot be reproduced in other “in vitro” system (e.g. GPCRs in general).
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: December 15, 2015
    Assignee: Ablynx N.V.
    Inventors: Christophe Blanchetot, Martine Smit, Regorius Leurs, Sven Jähnichen, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot
  • NANOBODIES AGAINST TUMOR NECROSIS FACTOR-ALPHA
    Publication number: 20150353635
    Abstract: The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.
    Type: Application
    Filed: May 12, 2015
    Publication date: December 10, 2015
    Applicant: ABLYNX N.V.
    Inventor: Els Anna Alice Beirnaert
  • TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20150344568
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: April 29, 2015
    Publication date: December 3, 2015
    Applicant: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
  • Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
    Patent number: 9193780
    Abstract: The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: November 24, 2015
    Assignee: Ablynx N.V.
    Inventors: Anna Hultberg, Bram Maassen, Peter Vanlandschoot, Erik Depla, Catelijne Stortelers, Cornelis Theodorus Verrips, Steven Van Gucht, Jose Melero, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Robert Anthony Weiss, Nigel J. Temperton, Xavier Saelens, Bert Schepens, Alexander Szyroki, Michael Marie Harmsen
  • Nucleic acids encoding IL-6R-binding polypeptides
    Patent number: 9181350
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: November 10, 2015
    Assignee: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
  • BIOLOGICAL MATERIALS RELATED TO C-MET
    Publication number: 20150307612
    Abstract: The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.
    Type: Application
    Filed: October 1, 2012
    Publication date: October 29, 2015
    Applicant: Ablynx N.V.
    Inventors: Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Cedric Jozef Neotere Ververken, Tinneke Denayer
  • AMINO ACID SEQUENCES DIRECTED AGAINST CELLULAR RECEPTORS FOR VIRUSES AND BACTERIA
    Publication number: 20150299327
    Abstract: The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. Nanobodies specifically recognizing hCD4, hCXCR4, hCCR5, hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-BI, hClaudin-1, hClaudin-6 and hClaudin-9, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. Said amino acid sequences may be used to prevent human cell entry of HIV, HCV, adenoviruses, hantavirus, herpesvirus, echo-virus 1 and others.
    Type: Application
    Filed: February 20, 2015
    Publication date: October 22, 2015
    Applicant: Ablynx N.V.
    Inventors: Christophe Blanchetot, Martine Smit, Regorius Leurs, Sven Jähnichen, Dominique Schols, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot, Peter Verheesen
  • POLYPEPTIDES AND POLYPEPTIDE CONSTRUCTS COMPRISING SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST VON WILLEBRAND FACTOR
    Publication number: 20150299301
    Abstract: The present invention relates to polypeptides comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, gpIb and/or collagen, homologues of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting), methods and kits for screening for agents that modulate platelet-mediated aggregation and kits for the diagnosis of diseases related to platelet-mediated aggregation.
    Type: Application
    Filed: March 26, 2015
    Publication date: October 22, 2015
    Applicant: Ablynx N.V.
    Inventor: Karen Silence
  • Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
    Patent number: 9156914
    Abstract: The present application relates to amino acid sequences that are directed against and/or that can specifically bind to metalloproteinases from the ADAM family, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences, and to methods of preparing the same.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: October 13, 2015
    Assignee: Ablynx N.V.
    Inventors: Christophe Blanchetot, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard
  • Method for the production of variable domains
    Patent number: 9150640
    Abstract: The present invention provides methods for the expression and/or production of variable domains with a C-terminal extension that can be used for coupling of the variable domain to one or more further groups, residues or moieties. In the method of the invention a yield of at least 80% of variable domains with a cysteine containing C-terminal extension is obtained. Also variable domains are provided and polypeptides comprising one or more variable domains obtainable by the methods of the present invention, as well as compounds that comprise such variable domains and/or polypeptides coupled to one or more groups, residues or moieties.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: October 6, 2015
    Assignee: Ablynx N.V.
    Inventors: Hilde Stals, Veronique De Brabandere, Peter Schotte
  • AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM
    Publication number: 20150266958
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: October 30, 2014
    Publication date: September 24, 2015
    Applicant: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • AMINO ACID SEQUENCES DIRECTED AGAINST HER2 AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF CANCERS AND/OR TUMORS
    Publication number: 20150232562
    Abstract: The present invention relates to amino acid sequences and Nanobodies that are directed against Epidermal Growth Factor Receptor 2 (HER2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: January 8, 2015
    Publication date: August 20, 2015
    Applicant: Ablynx N.V.
    Inventors: Hilde Adi Pierrette Revets, Carlo Boutton, Hendricus Renerus Jacobus Mattheus Hoogenboom